Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations - ScienceDirect

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada, BMC Cancer

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 - Annals of Oncology

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy - Pires da Silva - 2020 - Cancer - Wiley Online Library

Full article: Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients

Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

IJMS, Free Full-Text

PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

MBM - Melanoma Brain Metastases

Advances in targeted therapy and immunotherapy for melanoma (Review)